Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
NASDAQ:NYXH

Nyxoah Q3 2026 Earnings Date & Estimates

Nyxoah logo
$0.86 +0.02 (+2.64%)
Closing price 04:00 PM Eastern
Extended Trading
$0.84 -0.01 (-1.33%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nyxoah is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Nyxoah in Q3 2026

Nyxoah is expected to post earnings of -$0.3470 per share on revenue of $11.44 million. In the same quarter a year earlier Nyxoah reported -$0.74 per share on revenue of $2.31 million. Nyxoah last reported on August 6, 2026, posting -$0.67 per share and missing the -$0.47 consensus estimate. Nyxoah has beaten the consensus EPS estimate in 1 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.3470
Expected Revenue
$11.44 million
Prior-Year EPS
-$0.74
Prior-Year Revenue
$2.31 million
Expected Revenue Growth
+394.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.67 (Missed by -$0.20)
Last Quarter Revenue
$8.76 million
EPS Beat Rate
1 of last 8 quarters

Prepare for the Q3 2026 Call

Nyxoah Q3 2026 Earnings FAQ

Nyxoah (NASDAQ:NYXH) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Nyxoah's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Nyxoah to post earnings of -$0.3470 per share for Q3 2026.

The consensus revenue estimate for Nyxoah is $11.44 million for Q3 2026.

Nyxoah Earnings Headlines

Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026
October 26 at 5:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/26/3388608/0/en/nyxoah-to-release-third-quarter-2026-financial-results-on-november-5-2026.html
Analysts Have Conflicting Sentiments on These Healthcare Companies: EyePoint Pharmaceuticals (EYPT) and Nyxoah (NYXH)
October 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/EYPT/pressreleases/8306850/analysts-have-conflicting-sentiments-on-these-healthcare-companies-eyepoint-pharmaceuticals-eypt-and-nyxoah-nyxh/
Trump’s Plan To Cheat History
China has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely. Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years.tc pixel
October 26 at 1:00 AM  |  Porter & Company (Ad)
Nyxoah Update
October 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/instablog/47437728-stephen-tobin/6352607-nyxoah-update
Nyxoah (ENXTBR:NYXH) Stock Sees Fair Value Falls After Q2 Analyst Target Cuts
October 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/nyxoah-enxtbr-nyxh-stock-sees-101144818.html
Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026
October 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/19/3383354/0/en/nyxoah-announces-preliminary-results-for-the-third-quarter-of-2026-and-adjusts-revenue-guidance-for-2026.html
See More Nyxoah Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email.

About Nyxoah

Nyxoah (NASDAQ:NYXH) S.A. is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles. Unlike some traditional approaches, Genio is designed without an implanted breathing sensor or a stimulation lead placed in the chest.

The company has developed its business in European markets and has pursued commercialization in the United States. Genio has received regulatory clearances and approvals in various jurisdictions, including a CE mark in Europe and U.S. regulatory approval. Nyxoah is led by Chief Executive Officer Olivier Taelman, who has overseen the company’s efforts to advance and expand adoption of its sleep-apnea technology.

View Nyxoah Profile
Earnings Tools